Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.

Lane SS, Modi SS, Lehmann RP, Holland EJ.

J Cataract Refract Surg. 2007 Jan;33(1):53-8. Erratum in: J Cataract Refract Surg. 2007 Apr;33(4):564.

PMID:
17189793
3.

Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study.

Modi SS, Lehmann RP, Walters TR, Fong R, Christie WC, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso CE, Reiser H.

J Cataract Refract Surg. 2014 Feb;40(2):203-11. doi: 10.1016/j.jcrs.2013.07.042. Epub 2013 Dec 15.

4.
5.

Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery.

Zaczek A, Artzen D, Laurell CG, Stenevi U, Montan P.

J Cataract Refract Surg. 2014 Sep;40(9):1498-505. doi: 10.1016/j.jcrs.2013.12.023.

PMID:
25135542
6.

Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.

Maxwell WA, Reiser HJ, Stewart RH, Cavanagh HD, Walters TR, Sager DP, Meuse PA.

J Ocul Pharmacol Ther. 2008 Dec;24(6):593-9. doi: 10.1089/jop.2008.0023.

PMID:
19040348
7.

Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial.

Heier J, Cheetham JK, Degryse R, Dirks MS, Caldwell DR, Silverstone DE, Rosenthal A.

Am J Ophthalmol. 1999 Mar;127(3):253-9.

PMID:
10088733
8.

Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.

Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR; Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group.

Ophthalmology. 2011 Nov;118(11):2120-7. doi: 10.1016/j.ophtha.2011.04.035. Epub 2011 Jul 16.

PMID:
21762992
9.

Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.

Miyake K, Ota I, Miyake G, Numaga J.

J Cataract Refract Surg. 2011 Sep;37(9):1581-8. doi: 10.1016/j.jcrs.2011.03.052.

PMID:
21855758
10.

Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.

Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A.

Ophthalmology. 2001 Feb;108(2):331-7.

PMID:
11158809
11.

Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.

Sahu S, Ram J, Bansal R, Pandav SS, Gupta A.

J Cataract Refract Surg. 2015 Oct;41(10):2043-8. doi: 10.1016/j.jcrs.2015.10.061.

PMID:
26703278
12.

Ketorolac versus nepafenac in cataract surgery.

McCulley JP.

J Cataract Refract Surg. 2008 Mar;34(3):345-6; author reply 346. doi: 10.1016/j.jcrs.2007.11.023. No abstract available.

PMID:
18299048
13.

Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.

Walters TR, Goldberg DF, Peace JH, Gow JA; Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group.

Ophthalmology. 2014 Jan;121(1):25-33. doi: 10.1016/j.ophtha.2013.07.006. Epub 2013 Sep 8.

PMID:
24021896
15.
16.
17.
18.

Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.

Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.

Ophthalmology. 2007 Sep;114(9):1653-62. Epub 2007 Apr 19.

PMID:
17445902
19.

Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.

Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T, El-Defrawy SR.

J Cataract Refract Surg. 2012 Sep;38(9):1537-43. doi: 10.1016/j.jcrs.2012.04.034. Epub 2012 Jul 15.

PMID:
22795976
20.

Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.

Tzelikis PF, Vieira M, Hida WT, Motta AF, Nakano CT, Nakano EM, Alves MR.

Br J Ophthalmol. 2015 May;99(5):654-8. doi: 10.1136/bjophthalmol-2014-305803. Epub 2014 Nov 10.

PMID:
25385061
Items per page

Supplemental Content

Write to the Help Desk